ArticlePorcine health management2026
Randomized controlled single-farm field evaluation of an autogenous Mycoplasma hyosynoviae bacterin: lameness treatments and exploratory serology.
Article in Porcine health management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycoplasma hyosynoviae arthritis contributes to antimicrobial use and reduced welfare in fattening pig production. No commercial vaccines are available, and the efficacy of autogenous vaccines remains poorly documented. This study aimed to evaluate the effect of an autogenous M. hyosynoviae vaccine on lameness occurrence, describe M. hyosynoviae antibody profiles over time, and assess such profiles in relation to lameness development. CASE PRESENTATION: Methods. A randomized, blinded, controlled field trial was conducted in a Norwegian fattening pig herd and its associated piglet-producing herd. Piglets received two intramuscular injections of either vaccine or saline at six and nine weeks of age. Lameness occurrence was monitored throughout the fattening period, and serum samples from a subset of pigs (n=118) were collected at 6, 8, 13, and 19–21 weeks of age for detection of M. hyosynoviae-specific IgG antibodies by T20 IgG ELISA. Data were analyzed using logistic regression models.
resultsA total of 737 pigs (383 vaccinated, 354 controls) were evaluated for lameness. The incidence of lameness treatments was 7.8% (95% CI: 5.1–10.5) in the vaccine group and 6.8% (95% CI: 4.2–9.4) in controls, with no significant difference between groups (OR=1.28, 95% CI: 0.76–2.17, p=0.354). Most lameness cases occurred during the first three weeks after arrival at the fattening farm. Vaccination was not associated with increased odds of serum IgG seropositivity by the T20 ELISA in an exploratory subset (OR=0.97, CI: 0.36–2.58, p=0.947). Antibody levels varied with sampling time; the highest levels were observed at the end of fattening.
conclusionsAutogenous vaccination with a Mycoplasma hyosynoviae bacterin at six and nine weeks of age was not associated with a measurable reduction in lameness treatments in this study, and vaccinated and control pigs showed similar T20 IgG ELISA antibody profiles. Results should be interpreted in light of study limitations, including diagnostic uncertainty, factors related to vaccination timing and early immune dynamics, and the exploratory nature of the serological analysis. These findings highlight the challenges of evaluating autogenous M. hyosynoviae vaccines in the field and underscore the need for further research on effective preventive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.